Azalea Therapeutics wins Endpoints 11 award, combines gene editing with CAR-T and raises $82 million

Azalea Therapeutics was named the winner of the Endpoints 11 2026 competition, highlighting its innovative approach in the biotech space.

The company’s platform merges precise gene‑editing techniques with CAR‑T cell therapy, aiming to create more effective and customizable treatments.

Co‑founders Jenny Hamilton, Justin Eyquem, Jennifer Doudna and Michael Fischbach lead the Berkeley‑based firm, which has now secured $82 million in funding from a group of key investors.